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Abstract: Sepsis-associated acute kidney injury (SA-AKI) is an independent predictor of 
increased mortality and morbidity. It is essential that further advances in the treatment of sepsis 
should prioritize targeted therapies in SA-AKI in order to improve these bleak outcomes. As 
yet, a unique therapy that effectively reduces the impact of acute kidney injury has not been 
demonstrated. However, the emergence of novel targeted therapies, perhaps in combination, 
has the possibility of significantly reducing the long-term sequelae of an episode of SA-AKI. 
In this review, we will focus on the shared etiology of these conditions and how this is managed 
with targeted therapy and finally the emerging novel therapies that may play an additional role 
to current treatment strategies.
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Introduction
Acute kidney injury (AKI) and the sepsis syndrome are complex heterogeneous condi-
tions with common risk factors. Severe sepsis and septic shock remain major causes 
of mortality and morbidity in intensive care units (ICUs) in developed countries, with 
sepsis long recognized as a precipitant of AKI. Adult patients with AKI in the context 
of sepsis have a mortality rate of 60%,1 while in children, this varies from 57% to 66%.2 
Furthermore, the long-term outcome of an episode of AKI during a critical illness has 
recently been shown to be associated with significant morbidity and mortality. Given 
these observations, it is essential that further advances in the treatment of sepsis should 
prioritize targeted therapies in sepsis-associated AKI (SA-AKI), in order to improve the 
bleak outcomes. Part of the reason that patients with SA-AKI appear disadvantaged is 
that they display a greater acuity of illness,3 manifest physiologically as lower blood 
pressure, tachycardia, worse pulmonary function (the ratio of partial pressure arterial 
oxygen to the fraction of inspired oxygen [PaO
2
/FiO
2
]) and pH, and a higher white blood 
cell count. This is reflected in the higher mortality observed in SA-AKI compared to 
nonseptic AKI, both in the ICU and in general wards, across all stages of AKI.4
The management of sepsis has been revolutionized, particularly outside the ICU, 
with emphasis placed on early intervention ensuring a standard of care focusing on 
the effective treatment of the underlying infection. However, to date, there is no single 
effective therapy that has been shown to alter the outcome of SA-AKI. Rather, the 
process of care seems to confer a survival benefit. In this review, we will focus on the 
emerging targeted therapies that may play an additional role to the current treatment 
strategies and provide improved outcomes over the coming years.
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Pathophysiology
The pathophysiology of SA-AKI is complex above and 
beyond the intravascular volume status and perfusion pres-
sure. While ischemia–reperfusion models or nephrotoxin-
induced renal injury may go some way toward explaining the 
pathogenesis for some AKI etiologies, in SA-AKI associated 
with a hyperdynamic circulation, the pathophysiology differs.
Recent research indicates inflammatory mediators caus-
ing tubular cell dysfunction and cell cycle arrest along with 
the associated microcirculatory dysfunction as the trigger 
for SA-AKI.5 This process is in keeping with cellular injury 
processes resulting in multiorgan dysfunction such as that 
seen in severe sepsis.
The overall pathophysiology is summarized in Figure 1.
Multiple cell lines contribute to the pathophysiology of 
the inflammatory response. At the microvascular level, this 
leads to localized stasis within blood vessels and the release 
of inflammatory cytokines, including the components that 
cause activation of the coagulation system. This is seen 
as an increase in the expression of microparticles (small 
100–1,000 nm vesicular bodies originating from activated or 
apoptotic cells). In particular, an association has been found 
between platelet-derived microparticles and the development 
of SA-AKI.6
AKI assessment
Although AKI is defined in terms of changes in serum 
creatinine from baseline, as well as the less-frequently 
measured urine output, these measures, particularly serum 
creatinine, are inadequate in the acute situation. Much 
recent research has led to the quest for novel biomarkers 
as an acute assessment of renal function at the onset of 
AKI. Indeed, biomarkers are now available in some areas of 
clinical practice, which are able to better predict the sever-
ity of AKI, particularly when associated with sepsis.7 The 
most promising of these are plasma and urinary neutrophil 
gelatinase-associated lipocalin and urinary interleukin (IL)-
18 and kidney injury molecule-1.8,9 These biomarkers are 
proteins that are upregulated in response to renal injury. 
Cystatin-C, a functional marker, was also a promising 
plasma marker, although one study of 327 patients dem-
onstrated no signal for SA-AKI.10
Sepsis assessment
As with AKI, there is a uniform approach to the definition 
of sepsis. The American College of Chest Physicians and 
the Society of Critical Care Medicine joint statement defines 
sepsis and severe sepsis.11 This requires the presence of 
 infection together with systemic manifestations, whilst severe 
sepsis is sepsis with sepsis-induced organ dysfunction and/
or tissue hypoperfusion.
Shared susceptibility
Shared risk factors for sepsis and AKI include the presence of 
immunocompromised and proinflammatory states (Table 1).
Of note is the finding that the distribution of pathogens 
causing SA-AKI is consistent with that of those causing 
severe sepsis in a general ICU setting. For nosocomial 
infections, Gram-positive bacterial pathogens predominate 
at around 50% compared to Gram-negative bacteria at 39% 
and fungal at 11%.12
Outcome of SA-AKI
Independent risk factors for mortality among patients with SA-
AKI include age, acute physiology and chronic health evalu-
ation (APACHE II) score, duration of mechanical ventilation, 
duration of mean arterial pressure <65 mmHg, commencement 
of renal replacement therapy (RRT), and Kidney Disease: 
Improving Global Outcomes (KIDGO) stage of AKI.13,14 
Risk prediction for AKI is well established with independent 
risk factors and risk prediction scoring systems described in 
the literature, which can be further targeted to SA-AKI. An 
GFR reduced due to systemic hypotension and preferential
efferent renal vasodilation
While RBF is maintained it is decreased as a relative
 fraction of entire cardiac output
Impaired renal autoregulation
Proinflammatory mediators and microvascular injury
 lead to progressive afferent constriction
Glomerular capillary hydrostatic pressure is insufficient for effective
glomerular filtration, resulting in sustained loss of filtration
This phenomenon may persist until tubular epithelium 
has regenerated
Therefore, despite the evolution of early hemodynamic 
derangements, the SA-AKI will persist for as long as the
proinflammatory insult continues
Figure 1 Pathophysiology of sepsis associated acute kidney injury.
Note: Data from Prowle and Bellomo.5
Abbreviations: GFR, glomerular filtration rate; RBF, renal blood flow; SA-AKI, 
sepsis-associated acute kidney injury.
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example is the  adaptation of current grading systems such as 
the use of KDIGO classification with  consecutive hours of 
oliguria following diagnosis of sepsis. This was performed in 
a retrospective analysis of 390 patients, 25% of whom devel-
oped SA-AKI (≥stage 2) with consecutive oliguria for 3 hours 
showing a fair predictive ability for ≥stage 2 AKI (area under 
receiver operating characteristic curve, 0.73; 95% confidence 
interval, 0.68–0.78) and oliguria for 5 hours demonstrating 
optimal accuracy (82%; 95% confidence interval, 79%–86%).15
With the advancement of imaging techniques includ-
ing functional studies, prognostic utility for AKI is avail-
able now. One promising modality is the use of Tc-99m 
2,3- dimercaptosuccinic acid renal cortical imaging, with 
statistically significant findings obtained in patients with 
SA-AKI for short-term survival (defined as discharged alive 
from ICU).16 However, the cost and practical implications 
of using this as a prognostic tool are yet to be considered.
In 2014, an observational study from the US demon-
strated a worse outcome with high plasma IL-6 levels taken 
in patients during the first 8 hours of RRT for SA-AKI.17 
Another European-based study similarly found a poor 
outcome with raised serum kynurenic acid, an end product 
of tryptophan metabolism, during early (within 96 hours) 
RRT for SA-AKI.18 A prospective observational study 
from ten centers demonstrated increased plasma neutrophil 
 gelatinase-associated lipocalin concentrations on presenta-
tion in patients with presumed sepsis who subsequently 
developed SA-AKI.19 Current conventional markers of 
inflammation, such as lactate, C-reactive protein, or procalci-
tonin, have not been shown to have this predictive power, with 
these markers decreasing slowly over time in both survivors 
and nonsurvivors. The use of an early predictor could be used 
as part of a protocol to tailor targeted therapies, although 
there are concerns that these may reflect the sepsis process 
in general, rather than specifically SA-AKI.
Importantly, there is increasing evidence that reversal of 
SA-AKI early (within 24 hours) corresponds to a survival 
benefit, when compared to persistent AKI, new AKI, and 
even in the absence of AKI. This was shown in a 2014 obser-
vational study by analysis of the Cooperative Antimicrobial 
Therapy of Septic Shock database from a cohort of over 
5,000 patients in Canada, US, and Saudi Arabia.20 This has 
two important ramifications: firstly, the targeted therapy to 
reverse SA-AKI may confer improved outcome and secondly, 
the ability to identify these patients and use of this data may 
add to the accuracy of predictive scoring systems.
Targeted therapies
It is worth considering the importance of current practice with 
regard to SA-AKI. After several reiterations of the surviving 
Table 1 Shared susceptibility
Shared susceptibility
Immunocompromised AKI Sepsis
Diabetes mellitus An independent risk factor for AKI. Most likely due to increased 
predisposition to hypoxia
Altered immunity with resultant predisposition to 
infection
Cirrhosis Hyperbilirubinemia, hypoalbuminemia, low intravascular volume 
due to capillary leak, and high infection risk all predispose to AKI
Impaired neutrophil function among other 
alterations in immunity predisposes toward infection
HIV Glomerular disease and nephrotoxicity from antiretrovirals 
predisposes to AKI/CKD
Malignancy Incidence and severity of AKI depend on type and stage of 
malignancy
Proinflammatory
ARDS ARDS is associated independently with the development of AKI
CKD CKD predisposes to AKI owing to reduced renal reserves and 
reduced clearance of cytokines. Survival for AKI secondary to 
CKD can be better than de novo AKI (likely due to lesser insult 
required to cause the AKI); however, long-term outcomes such 
as dialysis dependence is worse
Reduced renal clearance of inflammatory mediators, 
uremia leading to phagocyte dysfunction, and 
disruption of gastrointestinal barrier all predispose 
toward sepsis
Post-op Differing profiles for the risk of AKI have emerged following 
assessment of different types of major surgery. Specifically, 
there are several validated scoring systems following cardiac 
surgery for the risk of AKI. Mortality rates for post-op AKI have 
improved, but remain high
Note: Data from Heung and Koyner48 and Leelahavanichkul et al.49
Abbreviations: AKI, acute kidney injury; ARDS, acute respiratory distress syndrome; CKD, chronic kidney disease; HIV, human immunodeficiency virus; Post-op, post-operative.
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sepsis guidelines, there has been a significant reduction in 
mortality for all-comers with sepsis; however, this treatment 
has not translated into a beneficial reduction of the incidence 
or severity of AKI. Also, there are several studies which 
demonstrate that the use of early goal-directed therapy does 
not affect the incidence or outcome of AKI.13 With regard to 
potential therapies for AKI, these may be classified as those 
targeted to restore homeostatic balance (usual therapies) and 
novel therapies aimed specifically at SA-AKI.
Usual therapies
Fluids
Composition
The type of fluid used in the management of sepsis has been 
topical for some time with the results of quality research 
demonstrating a shift in global clinical management. Key 
events can be summarized as follows:
•	 2008; VISEP – A crossover study of pentastarch and 
intensive insulin therapy. In this study, hydroxyethyl 
starch (HES) was associated with increasing AKI and 
need for RRT.21
•	 2011; SAFE substudy – Possible improved mortality 
outcome with albumin.22
•	 2012; 6S study – HES 130/0.4 versus Ringer’s lactate in 
severe sepsis. Patients receiving HES had an increased 
risk of death and need for RRT.23
•	 2012; CHEST – Trend toward increased mortality with 
6% HES (Voluven 130/0.4) compared to 0.9% saline and 
significantly increased requirement of RRT with HES.24
•	 2015; Split Trial – No difference between saline and bal-
anced solutions in development of AKI.25
Despite this, other than optimizing fluid therapy for sepsis 
and good husbandry of critical care electrolyte management, 
there is a paucity of specific evidence for any fluid choice in 
SA-AKI except avoiding synthetic starches.
Positive fluid balance
A late positive fluid balance is an independent risk factor for 
mortality in severe sepsis. However, this is not associated 
with either protection against or risk of AKI.26 This was most 
recently confirmed in a retrospective analysis of SA-AKI with 
determination of fluid balance at onset of organ dysfunction, 
vasopressor initiation, and sepsis diagnosis.
Vasopressors
In the setting of a replete intravascular volume, the mainte-
nance of an adequate mean arterial pressure of 65 mmHg in a 
patient without preexisting hypertension aids in adequate end-
organ perfusion. Also, the current sepsis guidelines suggest the 
use of noradrenaline as first-line therapy with vasopressin as a 
second-line agent. Of interest is evidence from animal models 
demonstrating that vasopressin causes less tubular apoptosis, 
systemic inflammation, and renal damage, when compared to 
noradrenalin.27 The VANISH trial (VAsopressin vs Noradrena-
line as Initial therapy in Septic sHock: ISRCTN20769191) has 
now completed recruitment while the results are awaiting pub-
lication.28 Recent scientific meetings detail that the vasopressin 
group had reduced total pressor requirements and reduced need 
for RRT, however, with no change in the primary outcome, the 
number of renal failure free days as defined by stage 3 AKI.
Antimicrobial selection
It is emerging that in the event of SA-AKI, the risk–benefit 
profiling of antimicrobial choice may need to consider renal 
outcome also. This is evidenced recently by a German-based 
retrospective analysis of 1,159 patients which demonstrated 
that the use of vancomycin in patients with SA-AKI increases 
the probability of a prolonged need for RRT at ICU dis-
charge.29 Furthermore, the use of bactericidal antibiotics has 
been shown to be associated with a transient worsening of 
renal function and more inflammation in the acute period.30
Renal replacement therapy
Timing
There is no consensus on the optimal time to initiate RRT. 
Some retrospective and observational studies suggest that 
early implementation of RRT could improve the prognosis 
for these patients. However, this is not backed up by large 
studies. Recently, a retrospective review from the People’s 
Republic of China demonstrated no difference in outcome 
with early versus late RRT.31
Dosing
The IVOIRE study showed no improvement with  high-volume 
hemofiltration (HVHF) at 70 mL/kg/h compared to standard-
volume hemofiltration (SVHF) at 35 mL/kg/h with regard to 
mortality, hemodynamic profile, or organ function.32 Single 
randomized controlled trials (RCTs) have demonstrated the 
same findings.33 This result was further confirmed in a meta-
analysis of four trials concerning 470 participants. Pooled 
analysis did not show any mortality difference. Furthermore, 
adverse events such as hypophosphatemia and hypokalemia 
were more common with HVHF (>50 mL/kg/h).34 A recent 
Cochrane review pooled three much smaller trials and again 
found no benefit of HVHF.35 However, a basic tenet in the 
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survival from sepsis is early source control and appropriate 
antibiotic therapy. In many “high-volume” studies, no cor-
rection was made for antibiotic flux, and hence, patients may 
have been effectively underdosed.
Mode
Although there is evidence that continuous venovenous hemo-
diafiltration (CVVHDF) results in improved proinflammatory 
cytokine removal with a recent study showing reduced levels 
of vascular endothelial growth factor and other cytokines along 
with improved renal recovery when using CVVHDF compared 
to continuous venovenous hemofiltration (CVVH),36 there is 
little evidence to support one technique over another.
Specialized extracorporeal techniques
Following the disappointing progress with the timing and 
dosing of RRT, it has been suggested that targeted therapies 
may include specialized extracorporeal techniques such 
as high cutoff hemofilters and hemoadsorption34 Hemoad-
sorption for enhanced endotoxin and cytokine removal has 
been studied. Results from a prospective case series in 2013 
demonstrated a significant reduction of 37% in Sequential 
Organ Failure Assessment scores within 48 hours of initiation 
of CVVH with hemoadsorption, compared to a rise of 3% in 
Sequential Organ Failure Assessment scores in those without 
hemoadsorption.37 Extracorporeal therapy with polymyxin B 
reduced the proapoptotic activity in patients with sepsis.27 To 
date, a mortality benefit has not been shown, as evidenced 
by a larger RCT of polymyxin B from France.38
Perhaps moving on from targeted cytokine removal would 
be the ability to replace the endocrine and metabolic functions 
of the kidney beyond that of RRT. This may be achievable 
with bioartificial renal epithelial cell system therapy, which 
has been developed as a standard hemofiltration cartridge 
with human renal tubular cells attached along the inner sur-
face of hollow fibers. Such renal tubule assist devices (RAD) 
have been the subject of a Phase II trial. This multicenter 
trial involving 59 patients demonstrated significant mortality 
benefit (33% in RAD group and 61% in conventional RRT at 
28 days), with Kaplan–Meier analysis determining a survival 
advantage for 180 days. In addition, RAD was associated with 
greater renal recovery.39 If proven to offer survival benefit in 
SA-AKI, the production and distribution of RAD cartridges 
are an obstacle yet to be overcome.40
Novel therapies
Weak evidence exists for some of the more novel targeted 
therapies for both sepsis and SA-AKI, which have been 
described later. It is unlikely that there will be a single agent 
that is able to drastically alter SA-AKI outcomes, although 
combination therapy may well confer benefit.
Alkaline phosphatase
Alkaline phosphatase has been investigated as a treatment for 
AKI. While the mechanism of action remains incompletely 
understood, the underlying principle is dephosphorylation 
of endotoxins and attenuation of the inflammatory response. 
A prospective, randomized, double-blind, placebo-controlled 
trial in 2012 demonstrated a clear improvement in endog-
enous creatinine clearance (P=0.02) along with reduced 
requirement and duration of RRT after 28 days.41 The same 
study also measured urinary biomarkers and demonstrated 
significant decreases in kidney injury molecule-1 and IL-18, 
both described to have prognostic utility for RRT require-
ment. This followed from earlier studies which demonstrated 
the administration of alkaline phosphatase was associated 
with reduced expression of inducible nitric oxide synthase 
in the proximal tubule. Most recently, another Phase I trial to 
assess the pharmacokinetic profile and safety of recombinant 
alkaline phosphatase demonstrated an acceptable profile, 
thus enabling progress to further interventional studies in 
SA-AKI.42 This is currently recruiting.
Erythropoietin
Erythropoietin decreases apoptotic cell death. So, given the 
known pathophysiology of SA-AKI, it is a reasonable therapy 
to investigate. However, high-dose erythropoietin is known to 
cause vasoconstriction and an increased risk of thrombosis. 
Newer erythropoietins have no hematopoietic activity. This 
perhaps may translate into benefit for the SA-AKI patients.
Methylene blue
Methylene blue has the effect of scavenging nitric oxide (NO) 
and inhibiting nitric oxide synthase. During proinflammatory 
states, the induction of NO is associated with proximal tubu-
lar injury. Small ICU studies in the Netherlands demonstrate 
that short-term methylene blue infusion is associated with 
reduced NO production and reduced urinary excretion of 
renal tubular injury markers.43
Molecular approach
Human studies targeting single proinflammatory cytokines, 
for example, antitumor necrosis factor-a, IL-1b, and Toll-like 
receptor 4, inhibition have not met with success.44 However, 
dual targeted strategy with IL-1b and IL-18 could be a poten-
tial treatment option for sepsis with the recent animal studies 
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demonstrating an association between this gene, survival, and 
organ failure-free days.45
Soluble thrombomodulin has been considered following 
the unsuccessful intervention of activated protein C (APC). 
APC was withdrawn from clinical practice as a treatment 
for sepsis due to significantly increased bleeding events. 
APC was thought to prevent thrombosis and, thus, maintain 
adequate regional microcirculation. Thrombomodulin is a 
cofactor in generating APC and its use is thought to prevent 
regional thrombosis without causing systemic effects. The 
mechanism behind the prevention of AKI is thought to be 
related to reduced leukostasis and an anti-inflammatory effect 
owing to endothelial cell signaling. This AKI prevention may 
be independent of the anticoagulant effect. Clinical studies 
to show the efficacy in sepsis and SA-AKI are in progress 
(Phase 3 Safety and Efficacy Study of ART-123 in Subjects 
With Severe Sepsis and Coagulopathy; NCT01598831).
Immunomodulation
1,25-Dihydroxycholecalciferol upregulates cathelicidin. 
This has been shown to be a broad-spectrum antimicrobial 
polypeptide. Those animals with overexpression of this 
polypeptide have reduced susceptibility to bacterial infec-
tion. Unfortunately, several RCTs (a Phase IIa and a Phase II 
trial) have not reported any survival benefit with dosing of 
1,25-dihydroxycholecalciferol in sepsis.46
Ghrelin, a neuropeptide, shows a protective effect on 
kidneys by inhibiting proinflammatory cytokines, particularly 
tumor necrosis factor-a, in the kidneys. Ghrelin may hold 
promise for managing endotoxemia-induced AKI.
CVVH has an immunomodulatory effect, with the tran-
scriptional activity of IL-6 increasing during therapy with 
CVVH for sepsis.47 The issue that remains is that CVVH 
removes pro- and anti-inflammatory mediators in a nonse-
lective way.
Other novel therapies have been postulated, but as yet 
lack evidence in the field of SA-AKI (Table 2).
Conclusion
There appears to be a growing body of evidence that sepsis-
associated AKI is a pathophysiologically different entity from 
other types of AKI. As such, the assessment and prognostic 
tools used to assess severity of AKI will need to be considered 
carefully and there is evidence that this process has begun.
When it comes to the management of SA-AKI first prin-
ciples remain those that have evidence base. Such as that 
proposed by surviving sepsis guidelines and the general ICU 
management of end-organ optimization. However, further to 
Table 2 Other emerging novel therapies
Potential therapy Description/trial progress
PPAR-a Inhibition of proinflammatory molecules, including IFN and IL-1744
MSCs Used for some time in hematology-oncology, MSCs promote bone marrow recovery and transplant tolerance. In sepsis, 
MSCs reduce inflammation and AKI47
Anti-inhibitory PD-1 
and its ligand (PD-L1)
PD-1 and PD-L1 could contribute to immunosuppression in late sepsis. In animal models of sepsis, the use of anti-PD-1 and 
anti-PD-L1 improved survival50
Desferrioxamine Iron chelation therapy. Iron can cause cellular injury by inducing oxidative radicals. Pathogenic microbials secrete 
siderophores which chelate iron so impairing cellular processes. Therefore, microbial “iron starvation” is a potential 
strategy to counter sepsis
Hepcidin This agent also sequesters iron, with several studies demonstrating renal protection40
2-Methoxyestradiol This anticancer drug inhibits HIF-1a and NF-b. HIF, released as a consequence of sepsis, induces hypoxia and promotes 
proinflammatory cytokines. In animal models, 2-methoxyestradiol reduced mortality and SA-AKI complications51
Resveratrol A scavenger of reactive nitrogen species, with studies demonstrating diminished tubular oxidative stress, improved 
microcirculatory flow, prevention of SA-AKI, and improved survival51
Ethyl pyruvate Another antioxidant and free radical scavenger. Ethyl pyruvate reduced both mortality and AKI in animal models. Currently 
in Phase II trials52
Anthracycline A known chemotherapy drug. Reduced complications of sepsis owing to autophagy, the process of clearance of cellular 
debris44
a-MSH A melanocortin agonist. This has been shown to have anti-inflammatory and antiapoptotic activities40,53
S1P analogs, adenosine 
analogs, inducible NOS 
inhibitors, fibrates
These drugs have the potential to reduce injury for ischemic reperfusion injury. Whether or not this would translate into 
any protection against SA-AKI remains to be seen52
Products of heme 
catabolism, HO-1
Stress responsive HO-1 enzyme system has important antioxidant, anti-inflammatory, and antiapoptotic properties54
Abbreviations: a-MSH, a-melanocyte–stimulating hormone; AKI, acute kidney injury; HIF, hypoxia-inducible factor; HO-1, heme oxygenase-1; IFN, interferon; IL-17, 
interleukin-17; MSCs, mesenchymal stem cells; NOS, nitric oxide synthase; PD-1, programmed cell death protein 1; NF-b, nuclear factor beta; PPAR-a, peroxisome 
proliferator activated receptor-a; S1P, sphingosine 1 phosphate; SA-AKI, sepsis-associated acute kidney injury.
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this is the emergence of targeted therapies that may improve 
AKI. There is no argument that SA-AKI is an independent 
predictor of increased mortality, and the emergence of novel 
therapies proves to be an exciting development. However, the 
importance of adequate follow-up and specialist nephrology 
input will complete the intervention to reduce the long-term 
sequelae of an episode of SA-AKI.
Disclosure
The authors report no conflicts of interest in this work.
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